ARTICANZ - Beta (ver 0.9)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/ALK-inhibitor-first-generation
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/ALK-inhibitor-first-generation
3
trial(s) found.
NCT05987332
Advanced
Phase 2 / Phase 3
Recruiting
IDE196 (Darovasertib) in Combination with Crizotinib Versus Investigator's Choice of Treatment As First-line Therapy in HLA-A2 Negative Metastatic Uveal Melanoma (DAR-UM-2) (
IDE196-002
)
ALK inhibitor,first generation
MET inhibitor,type 1
PKC inhibitor
ROS1 inhibitor
Uveal melanoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3181 - Prahran - The Alfred Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT03947385
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study of IDE196 in Patients with Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions (
IDE196-001
)
PKC inhibitor
+ ALK inhibitor,first generation
Colorectal cancer
Cutaneous melanoma
Solid tumour
Uveal melanoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
ACTRN12621000991819
Advanced
Not Applicable
Status unknown
A Feasibility Trial of Patient Derived Cell Culture (PDCC) Chemosensitivity in Head and Neck Carcinoma (HNC) (
PDCCiHNC
)
ALK inhibitor
ALK inhibitor,first generation
ATR inhibitor
BCR-ABL1 inhibitor
BCR-ABL1 inhibitor,second generation
CDK4/6 inhibitor
CDK4 inhibitor
CDK6 inhibitor
CRAF/FLT3/KIT/PDGFR/VEGFR inhibitor
CRAF inhibitor
Carboplatin
Ceralasertib
Cisplatin
Crizotinib
Dactolisib
Dasatinib
Docetaxel
Doxorubicin
EGFR inhibitor
EGFR inhibitor,first generation
Erlotinib
Etoposide
FLT3 inhibitor
Fluorouracil
Gemcitabine
Itraconazole
JAK1/JAK2 inhibitor
JAK1 inhibitor
JAK2 inhibitor
KIT inhibitor
MET inhibitor
MET inhibitor,type 1
Methotrexate
PDGFRA inhibitor
PDGFR inhibitor
PI3K/mTOR inhibitor
PI3K inhibitor
Paclitaxel
Palbociclib
Pemetrexed
RAF inhibitor
ROS1 inhibitor
Ruxolitinib
SMO inhibitor
SRC inhibitor
Sorafenib
VEGFR inhibitor
Vinorelbine
Vistusertib
YES1 inhibitor
anthracycline
antifolate
antimetabolite
cancer therapy
cancer therapy,ALK-targeting
cancer therapy,ATR-targeting
cancer therapy,BCR-ABL1-targeting
cancer therapy,CDK4-targeting
cancer therapy,CDK6-targeting
cancer therapy,CRAF-targeting
cancer therapy,EGFR-targeting
cancer therapy,FLT3-targeting
cancer therapy,JAK1-targeting
cancer therapy,JAK2-targeting
cancer therapy,KIT-targeting
cancer therapy,MET-targeting
cancer therapy,PDGFR-targeting
cancer therapy,PDGFRA-targeting
cancer therapy,PI3K-targeting
cancer therapy,RAF-targeting
cancer therapy,ROS1-targeting
cancer therapy,SMO-targeting
cancer therapy,SRC-targeting
cancer therapy,VEGFR-targeting
cancer therapy,YES1-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
cancer therapy,mTORC2-targeting
cytotoxic chemotherapy
fluoropyrimidine
mTORC1/mTORC2 inhibitor
mTORC1 inhibitor
mTORC2 inhibitor
mTOR inhibitor
platinum-based antineoplastic agent
taxane
topoisomerase inhibitor
vinca alkaloid
+ ALK inhibitor,first generation
Head and neck cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (2)
Status unknown (1)
Recruitment Country and State
NSW (3)
QLD (1)
SA (1)
VIC (1)
WA (1)
Phase
Phase 1 / Phase 2 (1)
Phase 2 / Phase 3 (1)
Trial Type
Advanced (3)
Cancer Therapy Class
ALK
100%
MET
100%
ROS1
100%
PKC
67%
CTLA4
33%
PD-1
33%
PD-1/PD-L1
33%
MEK
33%
ATR
33%
BCR-ABL1
33%
CDK4
33%
CDK6
33%
CRAF
33%
EGFR
33%
FLT3
33%
JAK1
33%
JAK2
33%
KIT
33%
PDGFR
33%
PDGFRA
33%
PI3K
33%
RAF
33%
SMO
33%
SRC
33%
VEGFR
33%
YES1
33%
mTOR
33%
mTORC1
33%
mTORC2
33%
Facility
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (2)
3000 - Melbourne - Peter MacCallum Cancer Centre (1)
3181 - Prahran - The Alfred Hospital (1)
4102 - Woolloongabba - Princess Alexandra Hospital (1)
5011 - Woodville South - The Queen Elizabeth Hospital (1)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (1)
2050 - Camperdown - Chris O'Brien Lifehouse (1)
Cancer Type
Cancer
Solid tumour
Melanoma
Uveal melanoma
Colorectal cancer
Cutaneous melanoma
Gastrointestinal cancer
Lower gastrointestinal cancer
Skin cancer
Head and neck cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy